EPIX and Bracco settle Multihance patent feud:
This article was originally published in Clinica
Executive Summary
EPIX Medical and the Italian company Bracco have settled their legal dispute over EPIX's European patents on MRI contrast imaging agents. Cambridge, Massachusetts-based EPIX has granted Bracco a worldwide licence to the patents - owned by the Massachusetts General Hospital and exclusively licensed to EPIX - in return for a $10 million advance payment. Bracco has also agreed to withdraw its oppositions to the corresponding patent applications in Japan. The deal permits Bracco to market its Multihance MRI contrast agent for liver and central nervous system imaging in Europe and the US, though the product is awaiting US marketing clearance.